Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Janelle Zeihen worried she’d have to file for bankruptcy after learning she owed $250,000 for her Crohn’s disease treatment.  The Milwaukee nursing home worker thought her insurance was covering the ...

A drug called Entyvio, from Japanese giant Takeda Pharmaceutical Co., kept her symptoms in check. Out of pocket, without any subsidies, it costs $9,360 a dose, not counting the cost of infusing ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...

For adults with ulcerative colitis, the advised dosage of ENTYVIO is 300 mg given through intravenous infusion at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks. Treatment ...

If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio contains the active ingredient vedolizumab. Entyvio is used to treat the signs and symptoms of moderate to ...